Financial Data and Key Metrics Changes - In 2021, the company recognized $3.2 million in revenue, an increase from $2.9 million in 2020, primarily from research funding with Indivior [23] - R&D expenses rose to $12.8 million, up by $2.5 million compared to 2020, due to increased activities in the Dipraglurant and GABAB PAM programs [23] - G&A expenses were $5.8 million, slightly up from $5.7 million in 2020, attributed to higher insurance premiums [24] - The company ended the year with a cash position of CHF20.5 million, equivalent to $22.5 million [6][25] Business Line Data and Key Metrics Changes - The company has three clinical programs actively dosing patients, including Dipraglurant for blepharospasm and dyskinesia associated with Parkinson's Disease [3][26] - The pivotal Phase 2b/3 study for Dipraglurant in PD-LID began in Q2 2021, enrolling 140 patients [7] - The exploratory study for blepharospasm involves 15 patients and is expected to report data in Q2 2022 [12] Market Data and Key Metrics Changes - The market opportunity for Dipraglurant in dyskinesia associated with Parkinson's Disease is described as multi-billion dollars [7] - There are approximately 50,000 patients in the U.S. suffering from blepharospasm, with about 2,000 new cases annually [51] Company Strategy and Development Direction - The company aims to maintain the integrity and quality of its clinical studies despite delays caused by the pandemic [4] - A strategic collaboration with Indivior was extended, with an additional $4 million committed for research funding [5] - The company is focused on advancing multiple preclinical programs, including mGlu7 NAM for PTSD and mGlu2 NAM for mild neurocognitive disorders [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing clinical trials and the potential for significant data readouts in 2022 [27] - The company anticipates a promising outlook, highlighting the undervalued equity story and the potential for partnerships as clinical data emerges [27] Other Important Information - The company has made significant progress in its preclinical portfolio, with multiple drug candidates advancing towards IND-enabling studies [22] - The company is exploring non-dilutive funding opportunities for its PTSD program, which has garnered interest from governmental entities [43] Q&A Session Summary Question: Is enrollment for the PD-LID Dipraglurant study hastening as the Omicron wave recedes? - Management noted good momentum in enrollment as COVID impacts lessen, with encouraging activity across various sites [30] Question: What is the strategic positioning for Dipraglurant regarding different indications? - Management indicated that data from the blepharospasm study will inform future development strategies, with a focus on a strong signal from the exploratory study [35] Question: What is the timing for Indivior's decision on extending the collaboration? - The collaboration is currently under review, with discussions expected as the program reaches advanced stages of clinical candidate selection [42] Question: Can you provide guidance on cash burn and cash reach? - The company reported a cash burn of approximately CHF1.5 million per month, guiding cash availability into the first half of 2023 [46] Question: What is the market potential for the blepharospasm indication? - The company estimates around 50,000 patients in the U.S. with blepharospasm, highlighting the impactful nature of the condition [51] Question: When can we expect lead candidates in clinical trials for the GABAB PAM program? - The company anticipates moving candidates into IND-enabling studies by the end of 2022, with Phase 1 trials potentially starting in late 2023 [55] Question: Will positive results from the ADX71149 epilepsy study trigger a milestone payment? - Management clarified that the last milestone was received when the program entered Phase 2, and no further details on future milestones could be provided [58][59]

Financial Performance - Cash and cash equivalents increased to CHF 20.5 million at December 31, 2021, up from CHF 18.7 million at the end of 2020, representing an increase of CHF 1.8 million[9] - Total operating loss for 2021 was CHF 15.5 million, compared to CHF 12.2 million in 2020, reflecting an increase in R&D expenses[5] - Income decreased by CHF 0.7 million to CHF 3.2 million in 2021, down from CHF 3.9 million in 2020[7] - The net loss for the period was CHF 15.4 million in 2021, compared to CHF 12.9 million in 2020, with basic and diluted loss per share decreasing to CHF 0.45 from CHF 0.48[9] Research and Development - R&D expenses rose by CHF 2.4 million to CHF 12.8 million in 2021, primarily due to increased outsourced R&D costs[8] - The Phase 2 clinical trial for dipraglurant in blepharospasm is on track to report data in Q2 2022[3] - The Phase 2b/3 study for dipraglurant in dyskinesia associated with Parkinson's disease is expected to report data in H1 2023[3] - The Phase 2a clinical study of ADX71149 in epilepsy is on track to report data in Q3 2022[3] Strategic Collaborations and Funding - A strategic collaboration with Indivior was extended with an additional funding of $4 million[2] - The company completed the year with a strong cash position of $22.5 million, bolstered by a $10 million financing from Armistice Capital[2]

Addex Therapeutics Limited (NASDAQ:ADXN) Q4 2020 Earnings Conference Call March 11, 2021 10:00 AM ET Company Participants Tim Dyer - CEO Roger Mills - Chief Medical Officer Robert Lutjens - Head of Discovery Biology Conference Call Participants Operator Ladies and gentlemen, welcome to the Webex Conference of Addex Therapeutics regarding the announcement of the Full Year 2020 Financial Results. At our customer's request this conference will be recorded. As a reminder, all participants will be in a listen-o ...

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EX ...